Fujifilm/Kyowa Kirin biosimilars alliance looks to production cost benefits
This article was originally published in Scrip
Fujifilm and Kyowa Hakko Kirin have agreed to set up an equally owned Japanese joint venture for the development and commercialisation of biosimilar products, a major aim of which is to come up with innovative, cost-competitive manufacturing processes.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.